Savara (SVRA)

NasdaqMarked lukket

Savara Inc. er en klinisk bioteknologivirksomhed, der udvikler behandlinger til sjældne luftvejssygdomme med særligt fokus på tilstande, hvor der findes begrænsede godkendte behandlingsmuligheder. Selskabets arbejde er centreret om speciallægemidler til respirationssystemet, hvor sygdomsbiologi, administrationsform og patientpopulation kræver målrettede udviklingsstrategier frem for brede kommercielle primærsektormodeller.

Savaras ledende program er molgramostim, en inhaleret formulering af rekombinant humant granulocyt-makrofag-kolonistimulerende faktor, eller GM-CSF. Kandidaten undersøges til autoimmun pulmonal alveolær proteinose, ofte forkortet aPAP, en sjælden lungesygdom, hvor nedsat clearance af surfaktant fører til ophobning af materiale i alveolerne og kan reducere iltoverførslen. Ved at levere GM-CSF direkte til lungerne er molgramostim designet til at adressere den underliggende mangel i immunsignaleringen, som er forbundet med sygdommen.

Selskabets investeringscase er tæt knyttet til den kliniske og regulatoriske fremdrift for molgramostim, som er i fase 3-udvikling. Som mange biotekvirksomheder inden for sjældne sygdomme afhænger Savaras værdi af vellykkede forsøgsresultater, interaktioner med myndigheder, produktionsberedskab, beskyttelse af immaterielle rettigheder og evnen til at betjene en lille, men medicinsk betydningsfuld patientgruppe. Det opererer ikke som en diversificeret lægemiddelproducent; i stedet koncentrerer det ressourcerne om et snævert terapeutisk område, hvor specialviden og fokuseret klinisk eksekvering er centrale.

Savara har hovedsæde i USA og handles på Nasdaq under tickeren SVRA. Investorer følger typisk selskabet for udviklingen inden for sjælden lungemedicin, sene kliniske data, regulatoriske milepæle og den potentielle kommercielle mulighed for en inhalationsbehandling ved aPAP.

5.37USD
+0.00(0.00%)

Sidst opdateret

Markedsværdi
$1,103,320,281
P/E-forhold
P/FCF-forhold
P/S-forhold
Selskabsværdi
$1,091,629,281
Sektor
Materials
Branche
Pharmaceutical Preparations
Adresse
6836 BEE CAVE ROAD, AUSTIN, TX, 78746
globenewswire.com

SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Savara, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

24. jan. 2026, 17:38 PM
globenewswire.com

SVRA DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Savara Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA

06. nov. 2025, 02:57 AM
globenewswire.com

SVRA DEADLINE: ROSEN, HIGHLY RANKED INVESTOR RIGHTS COUNSEL, Encourages Savara Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA

03. nov. 2025, 00:47 AM
globenewswire.com

SVRA FINAL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Savara Inc. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA

31. okt. 2025, 00:32 AM
globenewswire.com

DEADLINE ALERT for QMCO, TROX, SVRA, FLYE: Law Offices of Howard G. Smith Reminds Shareholders of Opportunity to Lead Securities Fraud Class Actions

30. okt. 2025, 18:46 PM
globenewswire.com

LEVI & KORSINSKY ISSUES CORRECTION: Securities Fraud Class Action Against Savara Inc.

29. okt. 2025, 02:39 AM
globenewswire.com

SVRA DEADLINE ALERT: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Savara Inc. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA

28. okt. 2025, 03:10 AM
globenewswire.com

Deadline Alert: Savara Inc. (SVRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

27. okt. 2025, 17:00 PM
globenewswire.com

SVRA SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

26. okt. 2025, 14:31 PM
globenewswire.com

SVRA IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Savara Inc. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action – SVRA

25. okt. 2025, 01:55 AM
globenewswire.com

ROSEN, A LONGSTANDING LAW FIRM, Encourages Savara Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action– SVRA

22. okt. 2025, 00:47 AM
globenewswire.com

SAVARA CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Urges Savara, Inc. Investors to Contact the Firm Before November 7th Deadline

18. okt. 2025, 17:39 PM
globenewswire.com

SVRA Lead Plaintiff Deadline (11/7/25) Reminder: Savara Inc. Investors Should Contact Robbins LLP for Information About the Class Action Lawsuit

17. okt. 2025, 22:52 PM
globenewswire.com

Savara Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before November 7, 2025 to Discuss Your Rights – SVRA

16. okt. 2025, 22:00 PM
globenewswire.com

SVRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Savara Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

16. okt. 2025, 18:00 PM
globenewswire.com

SVRA DEADLINE ALERT: Savara Inc. Investors Encouraged to Contact Kirby McInerney LLP Before Important Deadline in Lawsuit

16. okt. 2025, 00:00 AM
globenewswire.com

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Savara Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SVRA

15. okt. 2025, 22:00 PM
globenewswire.com

Deadline Alert: Savara Inc. (SVRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

14. okt. 2025, 19:57 PM
globenewswire.com

Class Action Filed Against Savara Inc. (SVRA) Seeking Recovery for Investors – Contact The Gross Law Firm

13. okt. 2025, 22:00 PM
globenewswire.com

SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

12. okt. 2025, 14:44 PM
Markedsværdi
$1,103,320,281
Selskabsværdi
$1,091,629,281
P/E-forhold
P/B-forhold
7.68
P/S-forhold
SV / EBITDA
-7.6
SV / salg
Indtjening pr. aktie
-0.68
Udbytteafkast
0%
P/FCF-forhold
P/CF-forhold
Fri pengestrøm
-$110,660,000
Afkast på egenkapital
-96.97%
Afkast på aktiver
-72.5%
Gæld / egenkapital
0.21
Likviditetsgrad
10.13
Hurtig likviditetsgrad
10.13
Kontantgrad
2.38
Gns. volumen
$1,552,685
Fundamentalt snapshot-pris
5.37

Finansielle rapporter er ikke tilgængelige for denne notering.

TypeIndberetningDatoHenvisning
edgar index10-Q — Savara IncSe indberetning
edgar indexS-8 — Savara IncSe indberetning
edgar index4 — Savara IncSe indberetning
form 4Form 4 — Lutz Robert MatthewSe indberetning
form 4Form 4 — Lutz Robert MatthewSe indberetning
edgar index4 — Savara IncSe indberetning
edgar index144 — Savara IncSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
edgar index8-K — Savara IncSe indberetning
eight k text8-K — 8-KSe indberetning
edgar index10-Q — Savara IncSe indberetning
edgar indexDEF 14A — Savara IncSe indberetning
edgar indexDEFA14A — Savara IncSe indberetning
edgar indexARS — Savara IncSe indberetning
edgar indexPRE 14A — Savara IncSe indberetning
edgar index4 — Savara IncSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
form 4Form 4 — Lowrance David LSe indberetning
edgar index10-K — Savara IncSe indberetning
edgar index8-K — Savara IncSe indberetning
eight k text8-K — 8-KSe indberetning
ten k section10-K — businessSe indberetning
ten k section10-K — mdaSe indberetning
ten k section10-K — risk_factorsSe indberetning
edgar indexSCHEDULE 13G/A — Savara IncSe indberetning
edgar index4 — Savara IncSe indberetning
edgar indexSCHEDULE 13G/A — Savara IncSe indberetning
form 4Form 4 — McCracken Joseph SSe indberetning
form 4Form 4 — McCracken Joseph SSe indberetning
edgar indexSCHEDULE 13G/A — Savara IncSe indberetning
edgar indexSCHEDULE 13G/A — Savara IncSe indberetning
edgar indexSCHEDULE 13G/A — Savara IncSe indberetning
edgar index8-K — Savara IncSe indberetning
eight k text8-K — 8-KSe indberetning
edgar indexSCHEDULE 13G — Savara IncSe indberetning
edgar index8-K — Savara IncSe indberetning
eight k text8-K — 8-KSe indberetning
edgar index4 — Savara IncSe indberetning
form 4Form 4 — RAMSAY DAVID ASe indberetning
edgar index144 — Savara IncSe indberetning
edgar index4 — Savara IncSe indberetning